Investment
Features
FeesSafety
Academy
More
Pluang+

Aberdeen's healthcare fund outperforms as uniQure shares surge on FDA gene therapy approval news

Market News
26 Aug 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Aberdeen Asset Management's Healthcare Opportunities Fund equity portion gained and outperformed its benchmark, driven by uniQure's strong share price rise after the FDA accepted its AMT-130 gene therapy data for accelerated approval in Huntington's disease. Boston Scientific weighed on performance due to slower Watchman device uptake and market share losses. The fund also initiated a position in Oruka Therapeutics, focusing on immunology biotech for psoriasis treatment. This performance highlights the fund's focus on innovative healthcare companies with promising treatments.

More News (BSX)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App